Summary Mice transplanted with NC carcinoma were treated with the thromboxane synthetase inhibitor dazmegrel (UK38485) or with nafazatrom (BAY G 6575), a compound that is reported to increase prostacyclin formation. Some experiments included the cytotoxic drugs methotrexate and melphalan. The tumours were excised under anaesthesia on day 14 or day 21 after transplanation, and weighed; some were extracted for prostanoids which were measured by radioimmunoassay. Mouse survival time was determined up to day 121, and cancer spread was determined by postmortem examination. The survival was increased by methotrexate and melphalan but not by the other drugs. Nafazatrom-treated mice tended to have lighter tumours. Although dazmegrel reduced the formation of thromboxane B2 during clotting of blood from normal mice, it did not affect the tumour yields of prostanoids. Nafazatrom had no effect on serum or tumour prostanoids. There were no obvious effects of the treatments on the recurrence of tumour in the excision scar, lung metastasis or spread to lymph nodes.
Effects of the arachidonate metabolites thromboxane A2 (TXA2) and prostacyclin (PGI2) on platelet aggregation are well known. The ability of TXA2 produced by platelets to cause their aggregation may normally be balanced by PGI2 which is inhibitory (Moncada & Vane, 1979) . Platelet aggregation is thought to be important in the haematogenous spread of some tumours, and Honn (1982) and his colleagues (Honn et al., 1981 (Honn et al., , 1983 suggested that circulating tumour cells, or vesicles shed from the primary tumour cells, disrupt the balance between PGI2 and TXA2 in favour of platelet aggregation. Experiments with intravenously injected B-16a melanoma cells showed that thromboxane synthesis inhibitors, PGI2, or nafazatrom (which has various actions including an increase of PGI2 formation), are antimetastatic (Honn, 1982; Honn et al., 1983) . A thromboxane synthesis inhibitor also reduced spontaneous metastasis from Lewis lung carcinoma (Honn, 1982) .
Furthermore, Donati ft al. (1982) found that tumour cells which produced highest amounts of TXA2 were most metastatic in mice. However, it is not known to what extent this applies to other tumours, and no studies relating to Drugs that inhibit cyclo-oxygenase usually reduce the size of NC tumours, and prolong host survival when given alone or with the cytotoxic drugs methotrexate and melphalan (Bennett et al., 1979 (Bennett et al., , 1982 . Cyclo-oxygenase inhibitors reduce both thromboxane and prostaglandin formation, but it is not known if the effect on thromboxane production contributes to the effects of indomethacin and flurbiprofen on tumour size and mouse survival.
The aims of the present study were: (i) to examine Honn's hypothesis, using nafazatrom or the thromboxane synthetase inhibitor dazmegrel in the mouse NC tumour model, (ii) to measure mouse survival time, tumour weight and prostanoid content and (iii) to study the effect of dazmegrel in combination with cytotoxic drugs.
Materials and methods
The NC carcinoma used in these studies originally arose spontaneously in the mammary region of a WHT/Ht mouse (Hewitt et al., 1976) , the same strain used in our experiments. Following local excision of this carcinoma there is a high incidence of local lymphatic spread, recurrence in the excision scar, and metastasis mainly to the lungs and mediastinum.
The mice were fed SDS No. 1 modified diet and had free access to water. On day 0, female WHT/Ht mice were injected s.c. into the left flank with 106 NC carcinoma cells prepared as described previously (Bennett et al., 1979 (Bennett et al., , 1982 In 4 other experiments, each with 10-15 female mice/group, nafazatrom 1 or 2mgkg-1 was given daily by mouth in 0.1 ml 50% syrup. Treatment started on the day prior to tumour transplantation and continued until death or the end of the experiment. The tumours were excised on day 21 and weighed. Some other tumours were homogenised and extracted for determination of prostanoids by radioimmunoassay as described above.
Body weights were measured twice-weekly throughout the experiments, starting from at least 2 weeks prior to tumour transplantation. Mice with advanced carcinomatosis or those who survived the duration of the experiments were killed humanely to prevent suffering (Bennett et al., 1982) . Mouse 
Results

Tumour weights
All these experiments were with female mice. Transplanted tumours were palpable by day 10, and then grew quickly. With day 14 excision the tumour weights were similar to controls in mice treated with dazmegrel 50mgkg-1 from day 1 or day 13 (P>0.5; Figure 1 ; day 13 data not shown).
In contrast, the tumours excised at day 21 from female mice given nafazatrom 1 or 2mgkg-1 from the day prior to transplantation were lighter than controls (P<0.003 and 0.03 respectively, Figure 1 ).
Serum prostanoids
Serum from blood removed 2 h after the last dose of dazmegrel 5 or 50 mg kg-1 contained less TXB2
and more 6-keto-PGF1 and PGE than controls (Table II) . Nafazatrom 1 or 2 mg kg-1 did not affect the amounts of serum prostanoids.
Tumour prostanoids Dazmegrel or nafazatrom had little or no effect on the tumour yields of 6-keto-PGF1a, PGE or TXB2 (Figure 2 Figure 3 ). Days survival Days survival Figure 3 Dazmegrel (dotted lines) had little or no effect on the survival of mice with resected tumours compared with vehicle controls (solid lines 
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Recurrence at the excision site seemed to be unaffected by dazmegrel, and the postmortem findings revealed no obvious effects on lung metastasis or spread to lymph nodes, regardless of the dose or timing of the treatment (Table IV) .
Methotrexate 2mg kg-given with melphalan 1.4mg kg-1 increased survival, but addition of dazmegrel made little or no further difference (Table III) .
Nafazatrom 1 or 2mg kg1 did not alter survival (Figure 4 ), spread to lymph nodes, or lung metastasis (Table IV) . The drug was not examined in combination with the cytotoxic drugs.
Discussion
The experiments with mouse serum ex vivo showed that the thromboxane synthetase inhibitor dazmegrel reduced thromboxane formation during blood clotting. There were also increased amounts of serum 6-keto-PGF1. and PGE, presumably due to diversion of substrate metabolism.
The inhibition of thromboxane synthesis would be expected to reduce the formation of platelet aggregates around tumour cells released into the bloodstream and, according to Honn's hypothesis, to reduce metastatic spread.
We obtained no evidence from the survival or postmortem data of an anti-cancer effect of dazmegrel. However, our experiments differ from those of Honn et al. (1981) and Honn (1982) in the types of tumour and thromboxane synthesis inhibitors, and in the method of assessment. They counted lung metastases after a fixed time (mainly following the intravenous injection of cancer cells), whereas we measured mainly survival and postmortem findings. Most of their experiments were with the B-16a melanoma whereas our tumour is a metastasizing adenocarcinoma originally of spontaneous origin. We chose a different thromboxane synthesis inhibitor, partly because dazmegrel is suitable for human use (Fischer et al., 1983) . Our studies with platelet thromboxane synthesis confirm that this drug is also active in mice. Perhaps the failure to alter metastasis via an effect on platelets might have been because the inhibition was not sufficiently strong or longlasting, or that diversion of blood prostanoid synthesis to PGI2 or PGE2 counteracts any benefit that might result from inhibition of thromboxane synthesis. Alternatively, it may be that inhibition of platelet thromboxane synthesis does not affect the spread of NC tumour. If so, the increase of survival by indomethacin or flurbiprofen in mice with this tumour (Bennett et al., 1982) is by a different action. Another factor may be that dazmegrel did not inhibit tumour thromboxane synthesis. This was surprising because dazmegrel is classified as a thromboxane synthesis inhibitor and acts as such in mouse blood ex vivo. However, Patrono et al. (1984) found that although dazoxiben and other drugs given to human subjects greatly reduced platelet thromboxane formation, they had only a weak effect on kidney thromboxane formation. Furthermore, Stork and Dunn (1985) reported that although the thromboxane synthetase inhibitor OKY-1581 abolished the increase of rat glomerular thromboxane production in response to nephrotoxic serum ex vivo, the drug had little effect on basal levels. It may be relevant that the amounts of prostanoids which we obtained by homogenising tumours in acid-ethanol approximate to basal levels (Bennett et al., 1973) . Honn (1982) did not measure prostanoids, so that we do not know if our lack of effect on tumour thromboxane formation explains the difference from his findings on metastasis. Nor can we deduce whether the reduction of tumour weight by indomethacin or flurbiprofen (Bennett et al., 1979 (Bennett et al., , 1982 involves inhibition of thromboxane synthesis.
As we have previously reported (Bennett et al., 1982 (Bennett et al., , 1985 , indomethacin, flurbiprofen, or methotrexate + melphalan prolong the survival of mice with excised transplanted NC tumours. This prolongation is greater when indomethacin or flurbiprofen are given together with the cytotoxic drugs. Dazmegrel given alone or with methotrexate + melphalan did not alter mouse survival. Apart from the lack of effect on tumour thromboxane synthesis, no alteration of survival would necessarily be anticipated with a thromboxane synthesis inhibitor since the prolongation with indomethacin seems to be prostaglandinmediated; the effect of indomethacin was counteracted by giving a long-acting PGE2 analogue (Bennett et al., 1985) .
Nafazatrom is reported to inhibit lipoxygenase activity and increase PGI2 production, and was found by Honn et al. (1983) to reduce the formation of lung metastases in mice injected with B-16a melanoma cells. However, we found no effect of the drug on the serum or tumour prostanoid content or host survival, although nafazatromtreated mice tended to have smaller tumours. The lack of effect on survi'Val is consistent with the failure of nafazatrom to sffect serum or tumour prostanoids, but again we do not know if this explains the difference from the results of Honn et al. (1983) since they did not measure prostanoids.
We therefore conclude that neither nafazatrom nor the thromboxane synthetase inhibitor dazmegrel are anticancer in the mouse NC tumour model. Our evidence argues against an important role for blood TXA2 and PGI2 in the spread of mouse NC carcinoma, but since the drugs did not affect tumour prostanoid synthesis no firm conclusion can be reached about roles of thromboxanes or PGI2 in tumour growth.
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